Holen Sie sich die Stockscreener-App
197.18
1.86%
3.60
Vorhandelsmarkt:
197.18
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$193.58
Offen:
$195.78
24-Stunden-Volumen:
957.76K
Relative Volume:
1.05
Marktkapitalisierung:
$21.83B
Einnahmen:
$11.28B
Nettoeinkommen (Verlust:
$1.07B
KGV:
21.75
EPS:
9.0657
Netto-Cashflow:
$1.33B
1W Leistung:
-1.92%
1M Leistung:
+1.01%
6M Leistung:
+12.62%
1J Leistung:
+9.72%
1-Tages-Spanne:
$194.15
$197.79
1-Wochen-Bereich:
$192.83
$201.04
52-Wochen-Spanne:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
197.18 | 21.83B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
469.35 | 174.42B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
178.97 | 126.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
541.31 | 42.70B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
126.67 | 35.78B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.20 | 35.07B | 3.77B | 449.25M | 240.68M | 7.8556 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now? - TradingView
Quest Diagnostics Prevails in Appeal Over 401(k) Fund Options - Bloomberg Law News
Quest Diagnostics StockWeekly outlook with earnings ahead - AD HOC NEWS
Is Quest Diagnostics Stock Underperforming the S&P 500? - inkl
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Study: UTI bacteria resist three common oral antibiotics - Stock Titan
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026 - GuruFocus
Quietly smarter diagnostics, Quest Diagnostics Quanum Enterprise Content Manager streamlines lab wor - AD HOC NEWS
Quest Diagnostics Inc (DGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quest Diagnostics Inc (DGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quest Diagnostics Inc (DGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Quest Diagnostics Inc (DGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quest Diagnostics Inc (DGX) Institutional Confidence - TradingKey
Quest Diagnostics Inc (DGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quest Diagnostics Inc (DGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quest Diagnostics Inc (DGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quest Diagnostics sets July 23 call for second-quarter results - Stock Titan
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report - Quest Diagnostics Newsroom
$21M in discounted Quest lab tests, aid for firefighters and cancer cluster - Stock Titan
Health Coalition Issues Open Letter to Health Minister to Stop Transfer of Lab Testing by Quest/Lifelabs to U.S. - GlobeNewswire Inc.
Quest Diagnostics Stock (US74834L1008): Analyst Actions Shape Monday Focus After Quiet Newsflow - AD HOC NEWS
Quest Diagnostics Stock (US74834L1008): Stock in focus after calm trading and no fresh catalyst - AD HOC NEWS
Quest Diagnostics Stock (US74834L1008): Valuation in focus after a quiet week - AD HOC NEWS
Quest Diagnostics Incorporated (DGX) stock price, news, quote and history - Yahoo Finance UK
Quest Diagnostics Inc (NYSE:DGX): A Top Dividend Stock with Sustainable Income and Growth Potential - ChartMill
Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 - GuruFocus
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare - Yahoo Finance
TD Asset Management Inc Sells 65,893 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc (DGX) Shares Surge 3.7% -- What GF Score o - GuruFocus
Quest Diagnostics Inc (DGX) Shares Surge 3.7% -- What GF Score of 83 Tells Investors - GuruFocus
Quest Diagnostics stock: Analyst estimates & ratings - MSN
4 Outpatient Home Health Stocks Benefiting From Industry Trends - TradingView
Fox Run Management L.L.C. Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Purchased by Cibc World Market Inc. - MarketBeat
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity - Stock Titan
Quest Diagnostics (DGX) Stock Analysis: Strong Upside Potential With Analyst Consensus - DirectorsTalk Interviews
Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 7,700 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Bank of New York Mellon Corp Has $116.39 Million Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
[144] QUEST DIAGNOSTICS INC SEC Filing - Stock Titan
How The Quest Diagnostics (DGX) Investment Story Is Evolving Without New Analyst Price Target Changes - Yahoo Finance
BNP Paribas Financial Markets Purchases 6,487 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Insider Sold Shares Worth $1,941,400, According to a Recent SEC Filing - marketscreener.com
Insider Sell: J. Davis Sells 10,000 Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics CEO sells $1.94 million in company stock - Investing.com UK
Quest Diagnostics CEO sells $1.94 million in company stock By Investing.com - Investing.com Australia
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):